General Questions

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception. Phexxi is not effective for the prevention of pregnancy when administered after intercourse.

Learn how Phexxi works by maintaining an acidic vaginal pH and reduces sperm motility.

One pre-filled applicator of Phexxi should be administered immediately before or up to 1 hour before each act of vaginal intercourse. If more than 1 act of vaginal intercourse occurs within 1 hour, an additional dose must be applied.1

Learn more about dosing and prescribing Phexxi.

A prescription for Phexxi consists of one box containing 12 individual applicators packed in foil pouches. Each applicator contains one 5-gram dose of Phexxi for single use. Patients using Phexxi for birth control may refill 11 times per year.

Learn more about dosing and prescribing Phexxi.

The AMPOWER Clinical Trial was a Phase 3, single-arm, open-label trial for women who were at risk of pregnancy, to demonstrate the safety and effectiveness of Phexxi over 7 cycles. Subjects were required to complete a daily eDiary to record coital information, study drug-use information, use of concomitant medications, including other vaginal products and other contraceptives, menses, and sign and symptom data for the subject or as reported to her by her partner.2,3

See the clinical trial results, including the effectiveness of Phexxi, a non-hormonal vaginal contraceptive gel.

Key inclusion criteriaa for women who participated in the clinical trial for Phexxi included3:

  • Healthy and sexually active, within the age range of 18 to 35 years old, at risk of pregnancy and desiring contraception
  • Had a normal, cyclic menses with a usual length of 21 to 35 days over the last 2 cycles or at least 2 consecutive spontaneous menses (21-35 days in length) since delivery, abortion, or after discontinuing hormonal contraception or hormonal therapy
  • Were at low risk for both human immunodeficiency virus (HIV) and sexually transmitted infectionsb
  • At the time of enrollment, had a single male sex partner for ≥3 months
  • Were willing to engage in at least 3 acts of heterosexual vaginal intercourse per cycle
  • Were willing to use the study drug as the only method of contraception over the course of the studyc
  • Were willing to report all information in a daily eDiary

aThis is not an exhaustive list of inclusion criteria.

bIn the opinion of the investigator, based on review of high-risk behaviors and exposures according to the Centers for Disease Control and Prevention (CDC) STI Guideline.

cWith the exception of emergency contraception in the event a subject engaged in vaginal intercourse but believed that the study drug was not used properly or she was at risk for pregnancy for any other reason.

See the clinical trial results, including the effectiveness of Phexxi, a non-hormonal vaginal contraceptive gel.

No. Phexxi is a non-invasive vaginal contraceptive gel that comes in pre-filled applicators. One pre-filled applicator of Phexxi should be administered immediately before or up to 1 hour before each act of vaginal intercourse.

Learn how Phexxi works by maintaining an acidic vaginal pH and decreasing sperm motility to prevent pregnancy.

Phexxi is a vaginal contraceptive gel that may be used with latex, polyurethane, and polyisoprene condoms; and vaginal diaphragms. Avoid Phexxi use with vaginal rings.

Learn about The Phexxi Patient and who Phexxi is right for.

Phexxi can be filled at a patient’s local pharmacy or delivered to their home through a specialty pharmacy. Evofem has partnered with specialty pharmacies to help your patients get Phexxi.

Contact an Evofem representative to learn more about options in your area.

Safety

No, there are no contraindications for Phexxi. However, Phexxi should be avoided in women who have had recurrent urinary tract infections or abnormalities, or are using a vaginal ring. Phexxi should also be avoided if the woman or her partner is allergic to any of the ingredients in Phexxi.1

Learn about The Phexxi Patient and who Phexxi is right for.

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis, and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females of reproductive potential with history of recurrent urinary tract infection or urinary tract abnormalities.

Learn about The Phexxi Patient and who Phexxi is right for.

Most common adverse reactions were vulvovaginal burning sensation, vulvovaginal pruritus, vulvovaginal mycotic infection,* urinary tract infection,†‡ vulvovaginal discomfort, bacterial vaginosis, vaginal discharge, genital discomfort, dysuria, and vulvovaginal pain. 9.8% of male partners reported local discomfort.1

Only 1.6% of clinical study participants discontinued due to Phexxi side effects. Two subjects discontinued due to male partner symptoms.

*Includes preferred terms (PT) vulvovaginal mycotic infection and vulvovaginal candidiasis.

Includes PTs urinary tract infection, streptococcal urinary tract infection, Escherichia urinary tract infection, and urinary tract infection bacterial.

Does not include PTs cystitis, kidney infection, and pyelonephritis.

Learn about The Phexxi Patient and who Phexxi is right for.

Phexxi has not been studied in breastfeeding women; however, Phexxi works locally and may be an appropriate choice for women who are breastfeeding.1

Learn about The Phexxi Patient and who Phexxi is right for.

In clinical studies, couples were allowed to engage in oral sex and no side effects directly related to oral sex were reported.3

Learn about the active ingredients in Phexxi and how they work by maintaining an acidic vaginal pH.

Phexxi is non-systemic, and systemic exposure is not expected to lead to safety concerns.1

Learn about the active ingredients in Phexxi and how they work by maintaining an acidic vaginal pH.

Patient Savings & Support

Yes, the  Phexxi Patient Brochure,  Instructions for Use Flashcard, the  Phexxi Savings Program, and the  Phexxi Patient Information  are all resources you can use with your patients. You can also direct them to Phexxi.com for more information, including Phexxi reviews from real users.

Visit the Phexxi Resources page to download patient resources.

Phexxi has preferred access on most insurance plans. Additionally, patient co-pay support is also available for your eligible patients.

Learn about the Phexxi Patient Savings Program.

INDICATION

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

LIMITATIONS OF USE

Phexxi is not effective for the prevention of pregnancy when administered after intercourse.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females with history of recurrent urinary tract infection or urinary tract abnormalities.

ADVERSE REACTIONS

Most common adverse reactions were vulvovaginal burning sensation, pruritus, mycotic infection, genital discomfort (including male partners); urinary tract infection, bacterial vaginosis, vaginal discharge, and dysuria. Patients should consult their healthcare provider for severe or prolonged genital irritation or urinary tract symptoms.

Advise the patient:

  • To discontinue Phexxi if they develop a local hypersensitivity reaction.
  • That Phexxi does not protect against HIV infection or other sexually transmitted infections.
  • Avoid Phexxi use with vaginal rings.

To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or you may contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Phexxi.

References:

  1. Phexxi® [Prescribing Information]. Evofem Biosciences, Inc.: San Diego, CA; June 2023.
  2. Thomas MA, Chappell BT, Maximos B, Culwell KR, Dart C, Howard B. A novel vaginal pH regulator; results from the phase 3 AMPOWER contraception clinical trial. Contracept X. 2020;2:100031.
  3. Data on file. Evofem Biosciences, Inc.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Few cases (0.36%) of adverse reactions of cystitis, pyelonephritis and other upper urinary tract infection (UTI) have been reported in Phexxi clinical studies. Of these, one case of pyelonephritis was considered serious and required hospitalization. Avoid use of Phexxi in females with history of recurrent urinary tract infection or urinary tract abnormalities.

ADVERSE REACTIONS

Most common adverse reactions were vulvovaginal burning sensation, pruritus, mycotic infection, genital discomfort (including male partners); urinary tract infection, bacterial vaginosis, vaginal discharge, and dysuria. Patients should consult their healthcare provider for severe or prolonged genital irritation or urinary tract symptoms.

Advise the patient:

  • To discontinue Phexxi if they develop a local hypersensitivity reaction.
  • That Phexxi does not protect against HIV infection or other sexually transmitted infections.
  • Avoid Phexxi use with vaginal rings.

To report SUSPECTED ADVERSE REACTIONS, contact Evofem at toll-free phone 1-833-EVFMBIO or you may contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information for Phexxi.

INDICATION

Phexxi is indicated for the prevention of pregnancy in females of reproductive potential for use as an on-demand method of contraception.

LIMITATIONS OF USE

Phexxi is not effective for the prevention of pregnancy when administered after intercourse.